01
Jun

The greatest promise of a new crop of immuno-oncology treatments likely comes from using them in combination with one another, clinicians say. And Bristol-Myers Squibb, maker of two such drugs, is looking to couple its blockbuster treatments in a package deal, rolling toward FDA approval with a tandem therapy.

…read more

Source: Bristol-Myers barrels toward approval with a blockbuster cancer combo

    

0 No comments